Form D · Biotechnology
Renue Life Sciences, Inc.
San Carlos, CA · CIK 0002158207
Offering snapshot reported Oct 14, 2026 · SEC filing
- Reported sold
- $250K Offering amount: $3M
- Investors reported
- 8 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Oct 2, 2026 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Oct 14, 2026 | Initial | $250,000 | No comparison | 8 | SEC filing |
Offering details
- Securities
- Security to be acquired, Other
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-601283
Issuance of Simple Agreements for Future Equity
Source: Form D, filed Oct 14, 2026. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No matching detailed fund disclosure was found in the latest imported ADV filings. This does not establish that the issuer has no adviser.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Phanidhar Kukutla | Director, Executive, Promoter |
| Jean Louis Lelogeais | Director |
| Samuel David Perli | Director, Executive, Promoter |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
1030 Brittan Ave. Room 257
San Carlos, CA, 94070
Phone: 732.692.3259
San Carlos, CA, 94070
Phone: 732.692.3259